Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

13 Jun 2014

Abstract excerpt

Owing to the more recent positive results with the anti-CD33 immunotoxin gemtuzumab ozogamicin, therapy against acute myeloid leukemias (AMLs) targeting CD33 holds many promises. Here, CD33 and CD123 expression on AML blasts was studied by flow cytometry in a cohort of 319 patients with detailed information on French-American-British/World Health Organization (FAB/WHO) classification, cytogenetics and molecular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24927407
DOI: 10.1038/bcj.2014.39

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 20 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemiaPMID 24927407Read ↗

High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation.Semantic proximity Read ↗

Targeting CD33 for acute myeloid leukemia therapy.Semantic proximity Read ↗

Targeting CD33 for Acute Myeloid Leukemia TherapySemantic proximity Read ↗

Gemtuzumab ozogamicin in acute myeloid leukemia.Semantic proximity Read ↗

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.Semantic proximity Read ↗

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia TreatmentSemantic proximity Read ↗

CD123 Is Consistently Expressed on NPM1-Mutated AML CellsSemantic proximity Read ↗

Differences in CD33 Intensity Between Various Myeloid NeoplasmsSemantic proximity Read ↗

CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotypingSemantic proximity Read ↗

CD33-CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells.Semantic proximity Read ↗

Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemiaSemantic proximity Read ↗

Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the FLT3-ITD/NPM1-MUT myeloblastic/monocytic bulk AML blastic populations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.